Follow us...


Search News Archives

News Channels


New Laboratory Products

Lab News

Research & Case Studies

Microscopy | Image Analysis

Separation Science

Brochures & Literature


Events | Webinars



Conferences | Events

Early Study Highlights Benefits of Point-of-Care Nucleic Acid Testing for Chlamydia and Gonorrhoea

publication date: Jun 23, 2014
author/source: cepheid

A recently published study has highlighted the economic and clinical benefits of incorporating a near patient nucleic acid amplification test (NAAT) for Chlamydia trachomatis and Neisseria gonorrhoeae into genitourinary medicine clinics.

Xpert CTNG cartridgeSponsored by leading molecular diagnostics company Cepheid, this prospective study estimates savings of up to £11.75m per annum from the adoption of laboratory-standard POC NAATs, such as Cepheid’s Xpert® CT/NG.

Recent advances in technology have enabled the latest generation of in-clinic analysers – such as Cepheid’s GeneXpert® series – to offer rapid, PCR-based testing at the point of patient care. This new generation of assays can provide laboratory quality results within 90 minutes, while significantly reducing space and staff training requirements. Dr Patrick Horner, co­author of the paper and Consultant Senior Lecturer in the School of Social and Community Medicine at the University of Bristol, explained: “The poor performance of traditional enzyme immunoassay POC tests for chlamydia and gonorrhoea resulted in poor uptake, as clinicians simply didn’t have confidence in the technology. Nucleic acid-based POC testing is a quantum leap from previous methods; it has the potential to substantially change the way we manage patients, leading to better-informed clinical decisions and helping to reduce patient anxiety.”

Dr Elisabeth Adams, Director and Founder of Aquarius Population Health, added: “One of the biggest potential areas of cost savings is the elimination of sub-optimal or inappropriate treatment. The availability of POC testing results at the patient’s appointment should ensure the most appropriate antimicrobial is used, avoiding treatment altogether for those who do not have an infection.”

more about cepheid international




Popular this Month...

Our Top 10 most popular articles this month


Today's Picks...




Looking for a Supplier?

Search by company or by product


Company Name:




Please note Lab Bulletin does not sell, supply any of the products featured on this website. If you have an enquiry, please use the contact form below the article or company profile and we will send your request to the supplier so that they can contact you directly.

Lab Bulletin is published by newleaf marketing communications ltd



Media Partners